- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Nov 2025 | 23 Oct 2025 |
| Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve quarterly results for the Quarter and Nine Months ended September 30, 2025 Unaudited Financial Results, both standalone and consolidated, for the quarter and half year ended 30 September 2025 Approval of Unaudited Financial Results, both standalone and consolidated, for the quarter and half year ended 30 September 2025. (As Per BSE Announcement Dated on: 13/11/2025) | ||
| Board Meeting | 12 Aug 2025 | 24 Jul 2025 |
| Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve financial results for the quarter ended June 30 2025. The Board in its meeting held today approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on: 12/08/2025) | ||
| Board Meeting | 25 Jul 2025 | 25 Jul 2025 |
| The Board in its meeting held today recommended the re-appointment of Mr. Mark Saldanha subject to the approval of the shareholders at the ensuing Annual General Meeting | ||
| Board Meeting | 11 Jul 2025 | 11 Jul 2025 |
| The Board in its meeting approved the Annual General Meeting related Matters and fixed August 8, 2025 as the Annual General Meeting date. | ||
| Board Meeting | 19 May 2025 | 8 May 2025 |
| Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve 1. To consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended March 31 2025. 2. To consider recommendation of dividend on the equity shares for the financial year 2024-25 if any. The Board in its meeting considered and approved of results for the year ended March 31 2025, recommendation of dividend and other related matters Recommended a final dividend of Rs. 0.80 per Equity Share (face value Re. 1 per share) for the financial year 2024-25. The dividend, if approved by the Members at the forthcoming Annual General Meeting (AGM) will be credited / dispatched within 30 days from the date of AGM. (As Per BSE Announcement Dated on :19.05.2025) | ||
| Board Meeting | 11 Feb 2025 | 22 Jan 2025 |
| MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve unaudited financial results, standalone and consolidated, for the quarter and nine months ended December 31, 2024. Kindly find enclosed outcome of Board meeting for the quarter ended and nine months ended December 31, 2024 (As Per BSE Announcement Dated on 11.02.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.